CDKN2A Human siRNA Oligo Duplex (Locus ID 1029)

CAT#: SR300743

CDKN2A (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each

Specifications

Product Data

• Purity: HPLC purified
• Quality Control: Tested by ESI-MS
• Sequences: Available with shipment
• Components: CDKN2A (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 1029)
  Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol
  Included - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml
• Stability: One year from date of shipment when stored at -20°C.
• Number of Transfections: Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM).
• Note: Single siRNA duplex (10nmol) can be ordered.

Reference Data

• RefSeq: NM_000077, NM_001195132, NM_058195, NM_058196, NM_058197, NM_001363763
• Synonyms: ARF; CDK4I; CDKN2; CMM2; INK4; INK4A; MLM; MTS-1; MTS1; P14; P14ARF; P16; P16-INK4A; P16INK4; P16INK4A; P19; P19ARF; TP16
• Summary: 'This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]'
• Performance Guaranteed: OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.
  
  For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).